Lantern Pharma Q3 net loss $4.5M; LP-300 shows 86% clinical benefit rate in lead-in

Lantern Pharma Inc.

2024-Q3 EPS reported -$1.39

Net loss of $4.5M ($0.42/share) vs $3.2M ($0.29/share) in Q3 2023; cash & securities $28.1M.
LP-300 Harmonic trial: 86% clinical benefit rate, 43% objective response in 7-patient lead-in; expanded to Japan and Taiwan.
LP-184 Phase 1a: 9 cohorts dosed, no DLTs; FDA Fast Track for GBM; Phase 1b/2a expected early 2025.
LP-284 Phase 1a: fourth cohort dosing, no DLTs; additional hematology sites planned; potential Phase 1b/2 by mid-2025.
R&D expenses $3.7M (up from $2.2M); G&A $1.5M ($1.3M); 10.8M shares outstanding.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.